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EgyptRegistering clinical trials (CTs) in public domains enhances transparency, increases trust in
research, improves participation and safeguards against publication bias. This work was done
to study the proﬁle of clinical research in Egypt in three CT registries with different scopes:
the WHO International CT Registry Platform (ICTRP), the continental Pan-African CT Reg-
istry (PACTR) and the US clinicaltrials.gov (CTGR). In March 2014, ICTRP, PACTR and
CTGR were searched for clinical studies conducted in Egypt. It was found that the number
of studies conducted in Egypt (percentage) was 686 (0.30%) in ICTRP, 56 (11.3%) in PACTR
and 548 (0.34%) in CTGR. Most studies were performed in universities and sponsored by uni-
versity/organization, industry or individual researchers. Inclusion of adults from both genders
predominated. The median number of participants per study in the three registries ranged
between 63 and 155. The conditions researched differed among the three registries and study
purpose was mostly treatment followed by prevention. Endpoints were mostly efﬁcacy followed
by safety. Observational:Interventional studies (i.e. clinical trials) represented 15.5%:84.5% in
ICTRP, 0%:100% in PACTR and 16.4%:83.6% in CTGR. Most interventions were drugs or
procedures. Observational studies were mostly prospective and cohort studies. Most CTs were
phase 3 and tested drugs or procedures. Parallel group assignment and random allocation
predominated. Blinding was implemented in many of trials and was mostly double-blind. We
38 A.A. Zeeneldin and F.M. Tahaconclude that CTs from Egypt in trial registries are apparently low and do not accurately reﬂect
clinical research conducted in Egypt or its potential. Development of an Egyptian CT registry is
eagerly needed. Registering all Egyptian CTs in public domains is highly recommended.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Clinical research is the type of scientiﬁc research that involves
human subjects and includes patient-oriented research, epide-
miologic and behavioral studies, and outcomes research and
health services research [1]. Clinical studies evaluate the effect
of interventions or exposures on biomedical or health-related
outcomes that include prevention, diagnosis and treatment of
diseases. They are broadly classiﬁed into observational and
interventional studies. Clinical trials (CTs) or interventional
studies are clinical studies in which participants are assigned
by researchers/investigators to receive one or more interven-
tions to assess their safety and efﬁcacy. In observational stud-
ies, participants are not assigned to interventions by the
investigators. Clinical trials are classically classiﬁed into 5
phases (0–4). Phase 0 studies are exploratory studies involving
very limited human exposure to an investigational new drug
(IND) for example screening studies and microdose studies
[2]. The primary aims of phase 0 studies are identifying, early
in the process of drug development, viable candidates and
eliminating those lacking promise with a potential reduction
in costs and time-to-ﬁrst-in-human testing. The endpoints
include evaluation of analogs for lead selection, modulation
of a molecular target in vivo, whole-body imaging for tissue
distribution/target binding afﬁnity, and agent pharmacokinet-
ics [*]. They are ethically acceptable [**]. Phase 1 studies aim to
ﬁnd out the drug’s most frequent and serious adverse events
and the drug metabolism and excretion. Phase 2 studies gather
preliminary data on efﬁcacy. Phase 3 studies gather more
information about safety and effectiveness. The randomized
controlled trial (RCT) is widely regarded as the gold standard
for evaluating health care interventions. Phase 4 studies occur
after marketing approval of a drug by authorities and aim to
gather additional information about a drug’s safety, efﬁcacy
and optimal use [2].
Participation in clinical trials is a voluntary action after
subjects are fully informed of the research and give their con-
sent [3]. Without participants, no CT can conclude. Clinical
trial registries (CTRs) facilitate the prospective registration
of CTs and the accessibility of their information by patients,
physicians, researchers and other interested stakeholders.
This enhances transparency, increases participation in CTs
and can eliminate publication bias that arises from publishing
positive trial results more than the negative ones [4,5]. Some
countries mandate CT registration; others do not ask for reg-
istration, but often strongly encourage it. CT registration is
mandated or recommended by many laws and policies includ-
ing U.S. Federal law, Declaration of Helsinki, European
Union Clinical Trials Directive, WHO Clinical Trials Direc-
tive, International Committee of Medical Journal Editors
(ICMJE) [6]. Currently, there are many CTRs with a scale
being global (e.g. WHO International Clinical Trials Registry
Platform [ICTRP]) [4], continental/regional (e.g. EU ClinicalTrials Register [EU-CTR] [7] and Pan-African Clinical Trials
Registry [PACTR] [8]), country-speciﬁc (e.g. US clinicaltri-
als.gov [6]) or companies and associations (e.g. International
Federation of Pharmaceutical Manufacturers Associations
[IFPMA]) [9].
ClinicalTrials.gov registry (CTGR) is a trial registry
hosted by the US National Institute of Health (NIH). It is
a governmental website. In February 2000, it was made avail-
able to the public as a registry of clinical trials information
on federally and privately funded trials conducted under
investigational new drug (IND) applications to test the effec-
tiveness of experimental drugs for serious or life-threatening
diseases or conditions. In September 2008, more information
on study participants and a summary of study outcomes,
including adverse events were made available. By 17th of
March 2014, CTGR contained 163,090 studies [10]. The idea
of a global clinical trial registry rose in the year 2004. The
WHO ﬁrst established the requirements of CTRs and a trial
registration data set. The focus then shifted to establishing
the two key elements of the platform: the International Clin-
ical Trials Registry Platform (the ICTRP Network) and a sin-
gle point of access (the ICTRP Clinical Trials Search Portal
(CTSP)). CTSP provides a single point of access for the iden-
tiﬁcation of trials in many contributing registries. CTSP was
launched in May 2007 and initially contained trial records
provided by three CTRs: the Australian New Zealand Clini-
cal Trials Registry (ANZCTR), CTGR and the International
Standard Randomised Controlled Trial Number (ISRCTN)
Registry. In addition to the above registries, the ICTRP Reg-
istry Network includes registries based in Brazil, China,
Cuba, EU-CTR, Germany, India (CTRI), Iran, Korea,
Japan, the Netherlands, PACTR, Sri Lanka, Thai and UK
[11]. By 17th of March 2014, ICTRP contained 271,811
records for 229,638 trials [4].
In early 2007, the Pan-African Clinical Trials Registry
(PACTR) was established by the South African Cochrane
Centre, in partnership with the European and Developing
Countries Clinical Trials Partnership and the Cochrane Infec-
tious Disease Group. In the initial phase, PACTR registered
trials in HIV/AIDS, tuberculosis and malaria to demonstrate
proof of concept. Once established, the goal of PACTR is to
become the registry of choice for any clinical trial conducted
in Africa [8]. On 25th of September 2009, PACTR was ofﬁ-
cially launched as a member of the WHO Primary Registry
Network in Abuja, Nigeria [12]. PACTR is presently the only
African member of the WHO Network of Primary Registers
and transfers all trial information to the WHO CTSP on a
quarterly basis. As of 17th of March 2014, PACTR contains
300 trials [8].
The aim of this work is to study the proﬁle of clinical trials
in Egypt in three clinical trial registries with different scopes:
the global ICTRP registry, the regional/continental PACTR
registry and the US CTGR.
The Egyptian clinical trials’ registry proﬁle 39Methods
The US clinical trial registry ‘‘clinicaltrials.gov; CTGR’’ was
searched for trials conducted in Egypt. In the ‘‘advanced search
http://clinicaltrials.gov/ct2/search/advanced, ‘‘Egypt’’ was
searched in the countries 1, 2 and 3 and the search yielded
548 entries. All entries were downloaded and manually scruti-
nized. The International Clinical Trials Registry Platform
‘‘ICTRP’’ Clinical Trials Search Portal (CTSP) (http://apps.
who.int/trialsearch/AdvSearch.aspx) was searched for trials
from Egypt and the search yielded 686 entries. The Pan-African
Clinical Trials Registry ‘‘PACTR’’ (http://www.pactr.org/) in
the advanced search and 73 entries for 56 studies were retrieved.
All searches were done on the same day (10th of March, 2014).
Analyses were done using Microsoft Excel 2010 and IBM
SPSS version 21.
The ICTRP was selected because it is an international reg-
istry that accepts studies from several registries including coun-
try-speciﬁc, regional and continental ones. Thus, it should be
exhaustive and includes almost all the registered studies. The
clinicaltrials.gov was chosen because it is the most mature reg-
istry and it preceded the ICTRP and thus it may contain stud-
ies not listed in the latter registry. The PACTR was chosen
because it is the only registry in the continent where Egypt lies
(Africa). Studying this latter registry would help in the process
of planning a proposed Egyptian registry.Results
As of 10th March 2014, the total numbers of studies included
in the ICTRP, CTGR and PACTRP were 229,638, 163,090Table 1 Total number, recruitment status and funding sources of E
CTGR
n (%)
Registry total 163,090 (100
Egypt’s total 548 (0.34)
Egypt’s rank 115
Recruitment
Recruiting 150 (27.4)
Not recruiting 85 (15.5)
Completed 295 (53.8)
Terminated/Withdrawn 18 (3.3)
Authorized 0 (0)
Not available 0 (0)
Results
Available 44 (8.0)
Not available 504 (92.0)
Funding source
University/Organization 384 (53.8)
Industry 273 (38.2)
Clinical Research Network 25 (3.5)
US Government (excluding U.S. Federal) 15 (2.1)
National Institutes of Health 17 (2.4)
Individual (researcher) 0 (0)
Other 0 (0)
CTGR: U.S. ClinicalTrials.gov Registry, ICTRP: WHO International Cl
Registry.
a Not included.and 645, respectively. Within ICTRP, Egypt ranked the 55th
with a total of 686 studies representing 0.30% of ICTRP total.
Within CTGR, Egypt ranked the 115th with a total of 548
studies representing 0.34% of its total. Within PACTRP,
Egypt ranked the 2nd (following South Africa) with a total
of 73 entries for 56 studies representing 11.3% of PACTRP
total (Table 1). CTGR and PACTRP are primary registries
that receive data directly from registerers while ICTRP
receives trial information from many primary registries. Main
sources of Egypt’s studies in ICTRP were CTGR (72.3%),
ANZCTR (13.6%), EU-CTR (7.7%), ISRCTN (4.2%) and
CTRI (2%). Comparing study titles showed that 72.3% of
studies in CTGR were repeated in ICTRP. However, none
of PACTRP studies was repeated in CTGR or in ICTRP.
Registration of Egypt’s clinical studies to both CTGR and
ICTRP started in 1999 and peaked in 2012 (Figs. 1 and 2).
Registration to PACTRP started in 2009 and peaked in
2013. Information on study completion was available in
CTGR only.
Recruitment status differed in the three registries. Active
recruiting status was encountered in 27.4% in CTGR, 19.1%
in ICTRP and 26% in PACRP. Completed status was encoun-
tered in 53.8% in CTGR and 33.9% in PACTRP and not men-
tioned in ICTRP. Study results were only available in CTGR
and only 8% of Egypt’s studies have results (Table 1).
In PACTRP and CTGR, most studies were sponsored by
universities/organizations followed by industry in CTGR or
individual researcher in PACTRP. None of PACTRP trials
were sponsored by industry. In ICTRP, industry sponsorship
predominated. The most common Egyptian sites were Cairo
University, Mansura University, Ain Shams University, Assiut
University and Alexandria University (Fig. 3). The mostgyptian studies in 3 trial registries.
ICTRP PACTR
n (%) n (%)
.0) 229,638 (100.0) 645 (100.0)
686 (0.30) 56 (11.30)
55 2
131 (19.1) 17 (30.4)
508 (74.1) 18 (32.1)
0 (0) 19 (33.9)
0 (0) 2 (3.6)
45 (6.6) 0 (0)
2 (0.2) 0 (0)
–a –a
–a –a
262 (38.2) 50 (89.3)
292 (42.6) 0 (0)
0 (0) 0 (0)
0 (0) 0 (0)
0 (0) 0 (0)
70 (10.2) 6 (10.7)
62 (9.0) 0 (0)
inical Trials Registry Platform, PACTR: Pan-African Clinical Trials
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Fig. 1 Egyptian studies in Clinicaltrials.gov according to the
registration, starting and completion years.
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Fig. 2 Egyptian studies in International Clinical Trials Registry
Platform (ICTRP) according to the registration and starting years.
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Clinicaltrials.gov (CTGR) and International Clinical Trials Reg-
istry Platform (ICTRP).
40 A.A. Zeeneldin and F.M. Tahacommon industrial sponsors were Novartis, Hoffman-La
Roche, Sanoﬁ, Pﬁzer, Eli Lilly and Bayer (Fig. 4).
Interventional studies were the most common type of stud-
ies in both CTGR and ICTRP (84%) followed by observa-
tional studies. PACTRP contained interventional studies
only (100%). Treatment was the most common study purpose
(69%) in CTGR and PACTRP followed by prevention
(Table 2). In CTGR, combined safety/efﬁcacy was the com-
monest endpoint (49.1%) followed by efﬁcacy alone (19.5%).
In the three registries, inclusion of both genders and adults
was the most common practice. The median number of
enrolled subjects was 155 in CTGR, 150 in ICTRP and 63 in
PACTRP.For interventional studies in CTGR and PACTRP, the
most common intervention was drug use (61.9%) followed
by procedure (12.8%). In the three registries, the commonest
study phase was phase 3 followed by phase 4 and phase 2
(Table 3). The commonest model was parallel group assign-
ment followed by single group assignment. The commonest
allocation method was the randomized method; blinding was
implemented in many of trials and was mostly double-blind.
In CTGR and ICTRP, observational studies constituted
almost 15% of the studies and were mostly prospective and
cohort studies (Table 4). None of the studies in PACTRP
was classiﬁed as observational.
Classiﬁcation of the conditions being researched differed
between the registries. Thus, no direct comparisons could be
made. In CTGR, the most researched conditions were Diges-
tive System Diseases, Cancers/Other Neoplasms, Symptoms/
General Pathology (Fig. 5). In ICTRP, the most common con-
ditions were Cancer, Hepatitis and Diabetes mellitus (Fig. 6).
In PACTRP, diseases and conditions being researched were
listed as individual conditions rather than grouped items. In
PACTRP, pregnancy and infertility were the commonest con-
ditions (n= 12; 21.4%) followed by surgical procedure
(n= 9; 16.1%), cancer (12.5%), pains (10.7%), and others
(39.3%).
Discussion
Egypt is the ‘‘Land of Civilizations’’ and is reputed worldwide
for its distinct 7000-year-old record of civilization and
immense wealth of knowledge [13]. Egyptian medicine was
dominant from approximately 2850 BC to 525 BC. The Egyp-
tian Imhotep was the ﬁrst physician ﬁgure to rise out of antiq-
uity. Imhotep was a known scribe, priest, architect,
astronomer and magician. He performed surgery, practiced
some dentistry, extracted medicine from plants and knew the
position and function of the vital organs. Surgical instruments
and surgical procedures such as circumcision are documented
on the paintings on the temples [14,15].
With its 82-million population, Egypt constitutes 1.2% of
the total world’s population [16]. However, it contributes only
0.34% of records in US clinical trial registry (Clinicaltrials.gov;
CTGR) and 0.30% in the WHO registry (ICTRP). It ranked
115th and 55th in both registries, respectively. We believe that
trials in Egypt are far more than those in the registries. Egypt
has 41 universities and 94 health-related faculties and medical
schools [17,18]. There are 24 Faculties of Medicine with up to
Table 2 Types, purposes, endpoints and enrollment of Egyptian studies in 3 trial registries.
CTGR ICTRP PACTR
n (%) n (%) n (%)
548 686 56
Study types
Interventional 458 (83.6) 580 (84.5) 56 (100.0)
Observational 87 (15.9) 104 (15.2) 0 (0)
Expanded access 3 (0.5) 2 (0.3) 0 (0)
Purpose
Treatment 379 (69.2) –a 41 (73.2)
Prevention 46 (8.4) –a 7 (12.5)
Supportive care 9 (1.6) –a 5 (8.9)
Diagnostic 6 (1.1) –a 2 (3.6)
Health services research 5 (0.9) –a 0 (0)
Screening 2 (0.4) –a 0 (0)
Education counseling training 0 (0) –a 1 (1.8)
Others/not mentioned 101 (18.4) –a 0 (0)
End point classiﬁcation
Safety/Eﬃcacy study 269 (49.1) –a –a
Eﬃcacy study 107 (19.5) –a –a
Safety Study 5 (0.9) –a –a
Pharmacokinetics study 3 (0.5) –a –a
Bio-equivalence study 1 (0.2) –a –a
Pharmacokinetics 1 (0.2) –a –a
Pharmacokinetics/dynamics 1 (0.2) –a –a
Others/not mentioned 161 (29.4) –a –a
Gender
Both 391 (71.4) 442 (64.4) 37 (66.1)
Female 137 (25.0) 176 (25.7) 18 (32.1)
Male 20 (3.6) 25 (3.6) 1 (1.8)
Not mentioned 0 (0) 43 (6.3) 0 (0)
Age
Child (<18 year) 37 (6.8) 68 (9.9) 4 (7.1)
Adult (18–65 year) 174 (31.8) 299 (43.6) 35 (62.5)
Senior (>65 year in WHO) 1 (0.2) 1 (0.1) 0 (0)
Child and adult 35 (6.4) 22 (3.2) 2 (3.6)
Adult and senior 233 (42.5) 142 (20.7) 12 (21.4)
Child, adult and senior 68 (12.4) 18 (2.6) 3 (5.4)
Number of enrolled subjects
Median (IQR) 155 (70–538) 150 (60–532) 63 (41–100)
CTGR: U.S. ClinicalTrials.gov registry, ICTRP: WHO International Clinical Trials Registry Platform, PACTR: Pan-African Clinical Trials
Registry, IQR: inter-quartile range.
a Not included.
The Egyptian clinical trials’ registry proﬁle 4134 departments in each faculty [19], 18 Faculties of Dentistry
with up to 12 departments in each faculty [20], 34 Faculties
of Pharmacy with up to 9 departments in each faculty [21], 12
Faculties of Nursing with up to 7 departments in each faculty
[22] and 6 Faculties of Physical Therapy with up to 8 depart-
ments in each faculty. In Egypt, there are more than 42,000 fac-
ulty members and 344,000 post-graduate students [17,18],
140,000 physicians, 18,200 dentists, 37,500 pharmacists
176,000 nurses and 35,000 physical therapists [23]. Clinical
research including clinical trials is an essential mandate for get-
ting Master and Doctorate Degrees. Moreover, clinical
research for publication is a mandate for promotion for faculty
members. Thus, the output of about 94 health-related faculties,
1400 departments and the huge number of health care profes-
sionals and faculty members is deﬁnitely more than the regis-
tered studies.The apparent low contribution of Egypt in trial registries
may be related to multiple factors. There is no Egyptian
national trial registry that hosts all trials running in the coun-
try. Many trials are not recorded in trial registries whether glo-
bal e.g. WHO ICTRP, regional/continental e.g. PACTRP or
other e.g. CTGR. There are no national mandates for trial reg-
istration. The reasons why some Egyptian trials are registered
can be imputed from examining the trial sponsorship where
most trials are sponsored by either pharmaceutical industry
or academic universities. Many of the pharmaceutical indus-
trial sponsors include an Egyptian site in addition to other
non-Egyptian sites. Industrial sponsors have to comply with
the international regulations that mandate trial registration
[6]. In addition to innovation, great majority of research con-
ducted in the Egyptian universities aims at publication in
renowned international journals that both increases author
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Table 3 Interventional studies from Egypt in 3 clinical trial
registries.
CTGR ICTRP PACTR
n (%) n (%) n (%)
Total 458 580 56
Intervention
Drug 316 (69.0) –a 30 (53.6)
Procedure 64 (14.0) –a 11 (19.6)
Biological 22 (4.7) –a 0 (0)
Device 16 (3.5) –a 0 (0)
Radiation 11 (2.4) –a 5 (8.9)
Dietary supplement 6 (1.3) –a 2 (3.6)
Behavioral 3 (0.7) –a 0 (0)
Other 20 (4.4) –a 8 (14.3)
Study phase
Phase 3 151 (33.0) 119 (20.5) 48 (85.7)
Phase 4 77 (16.8) 83 (14.3) 0 (0)
Phase 2 67 (14.6) 67 (11.6) 3 (5.4)
Phase 2|Phase 3 27 (5.9) 26 (4.5) 5 (8.9)
Phase 1|Phase 2 16 (3.49) 21 (3.6) 0 (0)
Phase 1 12 (2.6) 13 (2.2) 0 (0)
Phase 0 7 (1.5) 6 (1.0) 0 (0)
Phase 3/phase 4 0 (0) 4 (0.7) 0 (0)
Unknown 101 (22.05) 241 (41.6) 0 (0)
Model
Parallel assignment 320 (69.9) 326 (56.2) 50 (89.3)
Single group assignment 106 (23.1) 103 (22.4) 3 (5.4)
Crossover assignment 5 (1.1) 2 (0.4) 2 (3.6)
Factorial assignment 4 (0.9) 4 (0.7) 1 (1.8)
Not mentioned 113 (24.7) 145 (25.0) 0 (0)
Allocation
Randomized 355 (77.5) 380 (65.5) 48 (85.7)
Non-randomized 50 (10.9) 66 (11.4) 5 (8.9)
NM/Other 53 (11.6) 134 (23.1) 3 (5.4)
Masking
Open label 226 (49.3) 220 (37.9) 13 (23.2)
Double blind 168 (36.7) 182 (31.4) 24 (42.9)
Single blind 50 (10.9) 77 (13.3) 19 (33.9)
Unknown 114 (24.9) 101 (17.4) 0 (0)
CTGR: U.S. ClinicalTrials.gov registry, ICTRP: WHO Interna-
tional Clinical Trials Registry Platform, PACTR: Pan-African
Clinical Trials Registry.
a Not included.
Table 4 Observational studies from Egypt in 3 trial registries.
CTGR ICTRP PACTR
n (%) n (%) n (%)
87 104 0
Time perspective
Prospective 68 (78.2) 71 (68.3) 0 (0)
Cross-sectional 11 (12.6) 11 (10.6) 0 (0)
Retrospective 5 (5.8) 5 (4.8) 0 (0)
Not mentioned 3 (3.4) 17 (16.4) 0 (0)
Observational model
Cohort 41 (47.1) 44 (42.3) 0 (0)
Case control/case only/
case-crossover
28 (32.2) 25 (24.1) 0 (0)
Cross-sectional 0 (0) 7 (6.7) 0 (0)
Not mentioned 18 (20.7) 28 (26.9) 0 (0)
CTGR: U.S. ClinicalTrials.gov registry, ICTRP: WHO Interna-
tional Clinical Trials Registry Platform, PACTR: Pan-African
Clinical Trials Registry.
a Not included.
42 A.A. Zeeneldin and F.M. Tahacitation h-index [24] and advances the university ranking in the
university index [25,26]. Based on ICMJE [6], most renowned
journals ask author to provide details for trial registration
prior to publication. Otherwise, many Egyptian investigators
may be unaware of the presence of trial registries or the man-
date of registration. They may lack the appropriate training on
the detailed steps of registration. They may miss the support
from administrative research ofﬁces/facilities that can carry
out this job on their behalf. All of these factors contribute to
the low number of Egyptian trials in registries.
Clinical trial registries serve many beneﬁcial purposes [27]. It
is mandated by many laws and recommended by many author-
ities and bodies [6]. Of the three studies registries, the most
mature registry is CTGR followed by the ICTRP and lastly
the PACTRP. There are many similarities between search ﬁelds
in the three registries (Table 5). CTGR user-interface is simple
and enables easy, effective and accurate search. CTGR allowssearching by intervention, study phase, gender, age groups,
date of last update, sponsors/collaborators, results, completion
status. It displays the total number of studies and allows further
work on the results within the website. PACTRP allows further
search by study purpose, dates of start and end and principle
investigator name and country. However, interface was less
user-friendly and total results are not shown and could not be
worked within the website.
The most common diseases researched in the registries were
digestive system diseases, cancers/neoplasms, hepatitis, DM
and urogenital conditions. While most of these conditions are
included in the top Egyptian biomedical research topics [28],
yet the order is not perfectly matching. While hepatitis is the
Table 5 Comparing advanced search in three trial registries and suggestions for the proposed Egyptian registry.
Searchable items CTGR PACTRP ICTRP EGCRR
Simple interface + ± ± +
Study title/acronym or ID + + + +
Recruitment status + + + +
Study or trial type + +  +
Study purpose  +  +
Location (state and country list) +(L) +(FT) +(L&FT) +(L&FT)
Condition + + + +
Intervention +  + +
Study phase +   +
Gender +   +
Age +(C & A & S) +(Mn & Mx) +(C) +
Funding source + +  +
Dates of registration + + + +
Date of start  +  +
Date of end  +  +
Date of last update +   +
Sponsor/collaborators +  + +
Study results +   +
Completion status +   +
Display total number of results +  + +
Principal Investigator Name and country  +  +
Results can be worked out further in the site +   +
CTGR: U.S. ClinicalTrials.gov registry, ICTRP: WHO International Clinical Trials Registry Platform, PACTR: Pan-African Clinical Trials
Registry, EGCRR: Egyptian Clinical research registry (proposed), L: list, FT: free-test, C: children (<18 years), A: adults (18–65 years), S:
seniors (>65 years), Mn & Mx: minimum & maximum, (+): present, (): absent, (±): intermediate.
The Egyptian clinical trials’ registry proﬁle 43top research priority, it is the second in the registered trials.
Similarly, tumors were the 7th research priority but came ﬁrst
in the registered trials. Schistosomiasis is the second research
priority but the 4th in the registered studies. Reasons for the dif-
ference between the country’s research priorities and the actual
research done can be many. Researchers may be unaware of
these priorities. Mechanisms to enforce compliance may be
lacking. Most of the research is funded by universities or Indus-
try. Universities are not under the portage of the Ministry of
Health (MOH) and thus are not mandated to comply with its
set priorities. Industry enforces research topics that are within
their main interest e.g. to get a drug’s approval. Additionally
and as mentioned above, trials in the registries do not provide
a comprehensive picture of the biomedical research in Egypt.
Most of the studies were funded by either academic univer-
sities/organizations (38–54%) or industry (38–43%) and most
of the industries are multinational ones. Unfortunately, we
could not get information on the amount of funding and the
share of different stakeholders. In developed countries such
as US, investment in health research comes mainly from Indus-
try (64.4%), federal government (32.6%) and universities
(3.0%) [29]. Industry focuses on research with the best return
on investment (ROI). This may, or may not, coincide with
the national priorities. Thus, in developing countries such as
Egypt, governmental sponsorship should predominate to
enforce the national priorities.
While the mentioned registries were set to host clinical tri-
als, yet up to 17% of the entries refer to observational studies
i.e. non-trial studies. With time, the number of observational
studies in clinicaltirals.gov increased and the scope of registra-
tion widened. For example, the clinicaltrials.gov was initially
set to host clinical trials on IND for life-threatening condi-
tions, then it expanded to include other types of studies as well
as their results [10]. This was because much of the rationale forthe prospective registration of clinical trials applies to the reg-
istration of observational studies. Observational studies could
provide valuable information not achieved even by the well
conducted phase III clinical trials particularly related to drug
safety. Thus, many authorities and medical journals now rec-
ommend registering observational studies. Making both obser-
vational and interventional studies available in a single registry
will provide researchers and others with a more comprehensive
view of the growing evidence base [http://www.ncbi.nlm.nih.
gov/pmc/articles/PMC2952011/#!po=10.7143].
A limitation of the current study includes missing of some
data. However, this relates to the source registries and the
way they were designed (Table 5). For example, some registries
ask speciﬁcally for some information not requested by the oth-
ers making comparison unfeasible. Also, some of the informa-
tion requested may be either optional or may not have
exhaustive quality checks for what was entered. Optional ﬁelds
may be left blank. Even, if some data were entered there were
no exhaustive checks that read, understand and advise authors
for the necessary changes.
Conclusions
Clinical trial registration is mandated both ethically and from
a regulatory viewpoint. However, clinical trials from Egypt in
three trial registries are apparently low and do not accurately
reﬂect clinical research conducted in Egypt or its potential.
Recommendations
We recommend that Egyptian authorities immediately start a
national Egyptian clinical research registry (EGCRR) that
matches the well-developed registries particularly CTGR and
44 A.A. Zeeneldin and F.M. Tahahosts clinical trials as well as observational studies (Table 5).
We propose that EGCRR be hosted by the Egyptian Ministry
of Health, the Ministry of Higher Education or the Ministry of
Scientiﬁc Research. We recommend that all Egyptian clinical
research mandatorily get registered to this EGCRR immedi-
ately following ethical approval or exemption by the ethical
committees, and that investigators and institutions receive
appropriate training on research registration. In addition to
the several advantages of registration e.g. transparency,
enhanced participation and bias elimination, such Egyptian
registry (EGCRR) would ensure that research is not repeated
and that the country’s research activity can be assessed at
any time.
To ensure compliance with registration, there should be
some enforcement. This can be done at least at two levels;
ﬁrst funding may be linked to registration and second there
should be some legislation to mandate registration. We are
to see the ﬁrst Egyptian Clinical Research Law that will reg-
ulate and advances clinical research as well as protect
research participants’ rights, safety and well-being. This
Law should address registration. To protect the interests of
sponsors and investigators, they are highly encouraged to
patent and copy-right their investigational agents and intel-
lectual work prior to embarking on experimentation in
humans and hence registration. The registry should not reveal
the sensitive and secret aspects of an investigational agent e.g.
its chemical structure. Rather, it may refer to the investiga-
tional agent through a coding process. Access to secret and
sensitive information should be restricted and not publicly
available.
We also recommend setting of research support ofﬁces/
facilities that can carry out the job of registration or at least
provide the support and guidance. It is highly recommended
that Egypt sets a clear and frequently updates national
research priorities. These priorities should be decided on with
the involvement of all stakeholders including, but not limited
to, MOH, academic institutions, politicians, researchers, fund-
ing agencies, pharmaceutical companies and community repre-
sentatives. Priorities should be declared and enforced.
Research funding should be linked to compliance with these
priorities. To avoid skewing research toward the best interest
of international pharmaceutical industry, governmental fund-
ing of research should increase to encourage implementing
national priorities. National pharmaceutical industry should
be encouraged to engage more in research.
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